arrow
V

Victor Asua

infectious diseases research collaboration
H指数:11
被引数:1,160

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multiple local PfDHFR I164L haplotype expansions drive Plasmodium falciparum antifolate resistance in Uganda

多个局部PfDHFR I164L单倍型扩张驱动乌干达恶性疟原虫抗叶酸耐药性

2026-09-040
OA
Emergence and spread of Plasmodium falciparum PX1 polymorphisms associated with decreased susceptibility to antimalarials in Uganda

恶性疟原虫PX1多态性的出现与传播:与抗疟药敏感性降低相关联的乌干达研究

2026-08-170
OAAI
The MARC SE-Africa dashboard: Joining forces to counteract emerging antimalarial resistance in South and East Africa

MARC SE-Africa仪表盘:联合力量以对抗南非和东非地区新兴的抗疟疾耐药性

2026-05-010
OA
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial

乌干达6个月至10岁儿童中,治疗无并发症恶性疟原虫疟疾的青蒿琥酯-苯芴醇、青蒿素-阿莫地喹、双氢青蒿素-哌喹和青蒿素-哌喹的疗效:一项随机、开放标签、IV期临床试验

2025-08-190
PRE
Effectiveness of sulfadoxine–pyrimethamine plus amodiaquine and dihydroartemisinin–piperaquine for seasonal malaria chemoprevention in Uganda: a three-arm, open-label, non-inferiority and superiority, cluster-randomised, controlled trial

磺胺多辛-乙胺嘧啶联合阿莫地喹与双氢青蒿素-哌喹用于季节性疟疾预防化疗的有效性:一项三臂、开放标签、非劣效性和优效性、整群随机对照试验

2025-01-150
PRE
Evolution of Pfdhps and Pfdhfr mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso

布基纳法索Nanoro采用季节性疟疾化学预防前后Pfdhps和Pfdhfr突变的演变

2024-10-160
OAAI
Varied Prevalence of Antimalarial Drug Resistance Markers in Different Populations of Newly Arrived Refugees in Uganda
2024-06-141
PRE
Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda

乌干达疟原虫对青蒿素部分耐药性的演变

2023-08-2467
OA
Associations between Varied Susceptibilities to PfATP4 Inhibitors and Genotypes in Ugandan Plasmodium falciparum Isolates
2021-09-172
OA